Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829426 · ClinicalTrials.gov registry record · Phase 1
Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00829426: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00829426 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829426, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended release tablet) in healthy adult subjects administered under fasting conditions.
Interventions
- DRUG Alprazolam Extended-Release 3 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-06 |
| Est. Completion | 2005-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829426
The ClinicalTrials.gov registry entry for NCT00829426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alprazolam Extended-Release 3 mg Tablets is the first listed.
NCT00829426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829426 about?
NCT00829426 is a clinical study titled "Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions". This study will compare the relative bioavailability (rate and extent of absorption) of 3 mg Alprazolam Extended Release Tablets manufactured and distributed by TEVA Pharmaceuticals USA with that of 3 mg XANAX XR® Tablets by Pharmacia \& Upjohn Company following a single oral dose (1 x 3 mg extended...
What is the current status of trial NCT00829426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-06. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00829426?
The interventions under investigation include: Alprazolam Extended-Release 3 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00829426?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.